Osteoporosis News

Patients with secondary osteoporosis are 10 times more likely to have primary aldosteronism than patients without osteoporosis, according to findings from an Italian study.

Osteoarthritis, also known as degenerative joint disease, occurs when the cartilage that covers the end of joints breaks down. This loss of cartilage results in pain, swelling and trouble moving affected joints.

Postmenopausal women with osteoporosis who stop taking the monoclonal antibody denosumab risk a rapid loss of any bone mineral density gains and an increase in bone turnover markers, and should consider alternative therapies or avoiding a drug holiday, according to findings from a systematic review.

Bisphosphonates and denosumab increased bone mineral density in men with nonmetastatic prostate cancer who received androgen deprivation therapy, according to findings published in Annals of Internal Medicine.

EFORT Open Reviews is the new open access journal from EFORT and Bone & Joint Publishing. All articles are free to read online with no subscription required. Have you read these articles yet?

Agmen recently submitted a supplemental Biologics License Application to the FDA for denosumab for the treatment of people with glucocorticoid-induced osteoporosis, according to a company press release.

Amgen has received a Complete Response Letter for the Biologics License Application from the FDA asking the company to add safety and efficacy data from the ARCH and BRIDGE studies into the drug application for romosozumab as a treatment for postmenopausal women with osteoporosis, according to a company press release.

An otherwise healthy 16-year-old female patient was referred to the pediatric orthopedic clinic with a 1-year history of progressive left paraspinal thoracolumbar back pain and right lower extremity paresthesias. Initially, the paresthesias started on the dorsum and lateral aspect of the right foot with eventual progression more proximally over the lateral aspect of the leg and hip. The patient denied any history of trauma or an inciting event, as well as any constitutional symptoms. She maintained normal bowel and bladder function. The use of NSAIDs provided moderate back pain relief, but did not affect the paresthesias. The patient had not undergone any prior treatment. She initially presented to her general pediatrician, who obtained an MRI of the thoracic and lumbar spines that demonstrated multifocal osseous lesions that involved the thoracic and lumbar spines, as well as multiple rib lesions, which raised the concern for malignancy (Figure 1).

Adults treated with prednisolone and alendronate had reduced risk for hip fracture, major osteoporotic fracture, any fracture and nonvertebral fracture compared with adults treated with prednisolone only, according to findings published in JAMA.

Postmenopausal women with osteoporosis assigned denosumab therapy for up to 10 years saw sustained gains in bone mineral density and reductions in bone turnover with low fracture incidence vs. women assigned to placebo, according to an analysis of the FREEDOM extension trial.